Siemens Charts New Course with Major Healthineers Spin-Off

Siemens spins off 30% of Healthineers to shareholders, pivoting to industrial AI. Record €120B backlog supports the shift, despite stock decline and Healthineers' refinancing challenges.

Siemens AG is embarking on a profound strategic shift, moving to relinquish its controlling stake in its medical technology unit. In a landmark move, the industrial giant plans a direct spin-off of 30% of its Siemens Healthineers shares to existing Siemens shareholders. This decisive step signals the conglomerate's transformation into a more focused platform centered on industrial artificial intelligence.

Robust Fundamentals Underpin Strategic Pivot

The operational foundation for this corporate overhaul appears solid. For the first quarter, Siemens reported adjusted earnings per share of €2.80. The company's order backlog swelled to a record €120 billion, supported by a book-to-bill ratio of 1.12, indicating new orders are coming in faster than they can be fulfilled.

Despite this fundamental strength, the stock market's reaction has been muted year-to-date. Siemens shares are down 8.41% since the start of the year, closing at €220.65 on Monday. In a move to provide underlying support for the share price, management has been an aggressive buyer in the market, retiring 18 million shares in March alone as part of its ongoing buyback program.

Full Focus on an AI-Driven Industrial Future

The planned deconsolidation of Healthineers is designed to streamline Siemens' balance sheet and free up resources for its core industrial business. Shareholders will receive Healthineers stock directly into their depositories. Over the medium term, the Munich-based group aims to further reduce its remaining stake—currently about 67%—to a purely financial investment, completing its strategic exit from the healthcare sector.

Concurrently, and independent of the spin-off, Siemens is advancing its ambition in industrial AI. In partnership with NVIDIA, the company is pushing to establish fully AI-controlled production facilities. The initiative will launch with plants in Erlangen and Amberg, with these adaptive factories expected to come online starting in 2026. Siemens is also forging new international alliances, underscored by a recent agreement with the U.S. Department of Energy to modernize scientific infrastructure.

Challenges Await the Medical Technology Unit

For Siemens Healthineers, the path to greater independence involves significant financial hurdles. The medical device company anticipates negative impacts of up to €500 million this year from U.S. tariffs. A more substantial challenge involves refinancing €13.9 billion in loans, currently guaranteed by its parent company, on its own by 2028. This refinancing process will necessitate the maintenance of a solid investment-grade credit rating.

Siemens management is expected to provide concrete details on the structure and timeline of the transaction early in the second quarter. By the time the company presents its quarterly results on May 13, it must demonstrate that its remaining, more cyclical software and industrial business can generate sufficient operational strength to offset the costs associated with this significant transformation.